We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina and Merck Serono Collaborate
News

Illumina and Merck Serono Collaborate

Illumina and Merck Serono Collaborate
News

Illumina and Merck Serono Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Illumina and Merck Serono Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has formed a collaboration with Merck Serono, to develop a universal next-generation sequencing (NGS)-based oncology diagnostic. In addition to separate collaborations with AstraZeneca, Janssen Biotech, Inc., and Sanofi, Illumina and Merck Serono will work to create a universal test system for clinical trials of targeted cancer therapies, with the goal of a more comprehensive tool for precision medicine. 

Illumina is working with Merck Serono to develop assays that detect and measure multiple variants simultaneously to support clinical trials. The collaboration toward the universal cancer test will include test development, worldwide regulatory approvals, and global commercialization. In parallel, Illumina continues to collaborate with the key thought leaders of the Actionable Genome Consortium to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. 

"Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics," said Susan Herbert, Head of Global Business Development at Merck Serono. "This collaboration will strengthen the position of Merck Serono as a global leader in precision medicine in oncology." 

"This agreement is another step forward in realizing the promise of precision medicine," said Richard Klausner, MD, Illumina's Chief Medical Officer. "The US government's Precision Medicine Initiative, recently announced by President Obama, specifically outlines the need to expand genetically-based clinical trials as a key approach for developing better treatments for cancer. We are very excited to work with Merck Serono on this endeavor."

Advertisement